Ruplizumab (anti-CD40L) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab (anti-CD40L) has the potential for systemic lupus erythematosus disease research. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
26.2 kDa (Light Chain) & 51.5 kDa (Heavy Chain), under reducing conditions; 191.6 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
220651-94-5
Images
Ruplizumab (anti-CD40L) (Ab183448) - ELISA Immobilized Recombinant Human CD40 Ligand protein (rp169583) at 2.0 μg/mL can bind Ruplizumab (anti-CD40L) (Ab183448) with the EC50 of 24.77 ng/mL.
Ruplizumab (anti-CD40L) (Ab183448) - Flow Cytometry pLVX-puro-SYMX10-TNFSF5 (CD40L) - FL - HEK293 cells were stained with Ruplizumab (anti-CD40L) (Ab183448) and negative control protein respectively, washed and then followed by PE and analyzed with the FACS EC50 is 0.23 nM.
Ruplizumab (anti-CD40L) (Ab183448) - SEC The purity of Ruplizumab (anti-CD40L) (Ab183448) is more than 95% verified by HPLC.